Please Wait...

Impact of freezer failure on bone marker stability during serum sample storage

Yannick Lhoste, Philippe Vergnaud, Emeric Chassaing, Kafui Agbokou, Tanja Schubert, Bioclinica Lab, Lyon, France

Bone turnover markers are frequently used as pharmacodynamics biomarkers in clinical studies. Serum samples used to assess bone markers are collected at clinical sites, frozen, and subsequently sent to central laboratories in polystyrene boxes on dry ice. Upon arrival, serum samples are stored in -70°C freezers before being measured in batches.

We investigated the stability of the bone markers CTX-I (carboxy-terminal telopeptide of type 1 collagen), PINP (aminoterminal propeptide of type 1 collagen), Osteocalcin,  measured on Modular E170, Roche Diagnostics and BSAP (bone-specific alkaline phosphatase), measured on Access II, Beckman Coulter, after a simulation of freezer temperature increase caused by power or equipment failure.

Several aliquots of 6 different serum pools were stored in a full -70°C freezer for 20 days. Then, electricity failure was simulated and the resulting temperature increase was monitored over the following 60 hours. One aliquot of each serum pool was taken out of the freezer after 8, 24, 32 and 60 hours respectively and refrozen at -70°C until analysis.

 

RESULTS

Mean values

ng/ml

Baseline

(-75°C)

8 hrs.

(-53°C)

24 hrs.

(-45°C)

32 Hrs.

(-10°C)

60 hrs.

(+4°C for 1 hr.)

CTX-I

(p results)

0.462

0.462 (1.0)

0.459 (0.92)

0.461 (0.68)

0.459 (0.20)

P1NP

56.05

56.08 (0.83)

56.01 (1.0)

56.76 (0.40)

55.49 (0.83)

OC

27.59

27.85 (0.92)

27.63 (0.68)

28.14 (0.53)

28.15 (0.17)

BSAP

13.70

13.93 (0.40)

13.51 (0.83)

13.63 (1.0)

13.64 (1.0)

 

No statistical difference (Wilcoxon test) was observed for the 4 bones markers tested between baseline samples and the follow-up samples at 8, 24, 32 and 60 hours.

CONCLUSIONS

Freezer temperature failure over 60 hours does not affect the validity of the data generated for the 4 bone turnover markers tested.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

In case you missed it: Bioclinica announces additions to Software Solutions leadership. We welcome Guy Crossley, Ri… https://t.co/8VWOO3IPFD
Bioclinica (5 days ago)
Meet Chief Science Officer, Thomas Fuerst, Ph.D., to learn more about our musculoskeletal imaging services.… https://t.co/QFQ1HSV4uV
Bioclinica (6 days ago)
Going to SCOPE? Visit Bioclinica at booth 404! #SCOPE2020 https://t.co/m6akQrKkTL https://t.co/ahkmLMrKbU
Bioclinica (2 weeks ago)
We’re heading to #JPM2020, are you? Reach out if you’d like to learn how Bioclinica partners with sponsors to advan… https://t.co/Njnib3Tfju
Bioclinica (2 weeks ago)
Meet Chief Medical Officer, Michael O'Neal M.D., to learn more about our oncology imaging services.… https://t.co/RmtzYpZRmh
Bioclinica (2 weeks ago)
Are there risks in your clinical trial supply chain? Learn more here https://t.co/5MT0y4ooi9 https://t.co/xB2yRY6mft
Bioclinica (3 weeks ago)